Literature DB >> 20844043

Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus.

Sarah D Linnstaedt1, Eva Gottwein, Rebecca L Skalsky, Micah A Luftig, Bryan R Cullen.   

Abstract

Infection of resting primary human B cells by Epstein-Barr virus (EBV) results in their transformation into indefinitely proliferating lymphoblastoid cell lines (LCLs). LCL formation serves as a model for lymphomagenesis, and LCLs are phenotypically similar to EBV-positive diffuse large B-cell lymphomas (DLBCLs), which represent a common AIDS-associated malignancy. B-cell infection by EBV induces the expression of several cellular microRNAs (miRNAs), most notably miR-155, which is overexpressed in many tumors and can induce B-cell lymphomas when overexpressed in animals. Here, we demonstrate that miR-155 is the most highly expressed miRNA in LCLs and that the selective inhibition of miR-155 function specifically inhibits the growth of both LCLs and the DLBCL cell line IBL-1. Cells lacking miR-155 are inefficient in progressing through S phase and spontaneously undergo apoptosis. In contrast, three other B-cell lymphoma lines, including two EBV-positive Burkitt's lymphoma cell lines, grew normally in the absence of miR-155 function. These data identify the induction of cellular miR-155 expression by EBV as critical for the growth of both laboratory-generated LCLs and naturally occurring DLBCLs and suggest that targeted inhibition of miR-155 function could represent a novel approach to the treatment of DLBCL in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844043      PMCID: PMC2977875          DOI: 10.1128/JVI.01248-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.

Authors:  Andrew I Bell; Katherine Groves; Gemma L Kelly; Debbie Croom-Carter; Edwin Hui; Anthony T C Chan; Alan B Rickinson
Journal:  J Gen Virol       Date:  2006-10       Impact factor: 3.891

2.  Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155.

Authors:  Rebecca L Skalsky; Mark A Samols; Karlie B Plaisance; Isaac W Boss; Alberto Riva; M Cecilia Lopez; Henry V Baker; Rolf Renne
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

3.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells.

Authors:  Margaret S Ebert; Joel R Neilson; Phillip A Sharp
Journal:  Nat Methods       Date:  2007-08-12       Impact factor: 28.547

4.  A viral microRNA functions as an orthologue of cellular miR-155.

Authors:  Eva Gottwein; Neelanjan Mukherjee; Christoph Sachse; Corina Frenzel; William H Majoros; Jen-Tsan A Chi; Ravi Braich; Muthiah Manoharan; Jürgen Soutschek; Uwe Ohler; Bryan R Cullen
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

5.  Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice.

Authors:  Stefan Costinean; Nicola Zanesi; Yuri Pekarsky; Esmerina Tili; Stefano Volinia; Nyla Heerema; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

6.  A novel assay for viral microRNA function identifies a single nucleotide polymorphism that affects Drosha processing.

Authors:  Eva Gottwein; Xuezhong Cai; Bryan R Cullen
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Regulation of the germinal center response by microRNA-155.

Authors:  To-Ha Thai; Dinis Pedro Calado; Stefano Casola; K Mark Ansel; Changchun Xiao; Yingzi Xue; Andrew Murphy; David Frendewey; David Valenzuela; Jeffery L Kutok; Marc Schmidt-Supprian; Nikolaus Rajewsky; George Yancopoulos; Anjana Rao; Klaus Rajewsky
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

8.  Requirement of bic/microRNA-155 for normal immune function.

Authors:  Antony Rodriguez; Elena Vigorito; Simon Clare; Madhuri V Warren; Philippe Couttet; Dalya R Soond; Stijn van Dongen; Russell J Grocock; Partha P Das; Eric A Miska; David Vetrie; Klaus Okkenhaug; Anton J Enright; Gordon Dougan; Martin Turner; Allan Bradley
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

9.  Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells.

Authors:  Jan Mrázek; Simone B Kreutmayer; Friedrich A Grässer; Norbert Polacek; Alexander Hüttenhofer
Journal:  Nucleic Acids Res       Date:  2007-05-03       Impact factor: 16.971

10.  MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.

Authors:  Charles H Lawrie; Shamit Soneji; Teresa Marafioti; Christopher D O Cooper; Stefano Palazzo; Jennifer C Paterson; Helen Cattan; Tariq Enver; Rachel Mager; Jacqueline Boultwood; James S Wainscoat; Christian S R Hatton
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

View more
  107 in total

1.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

Review 2.  The role of microRNAs in Epstein-Barr virus latency and lytic reactivation.

Authors:  Eleonora Forte; Micah A Luftig
Journal:  Microbes Infect       Date:  2011-07-28       Impact factor: 2.700

Review 3.  The duality of oncomiR addiction in the maintenance and treatment of cancer.

Authors:  Christopher J Cheng; Frank J Slack
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 4.  EBV Noncoding RNAs.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 5.  Viral miRNAs and immune evasion.

Authors:  Isaac W Boss; Rolf Renne
Journal:  Biochim Biophys Acta       Date:  2011-07-05

6.  Unambiguous identification of miRNA:target site interactions by different types of ligation reactions.

Authors:  Stefanie Grosswendt; Andrei Filipchyk; Mark Manzano; Filippos Klironomos; Marcel Schilling; Margareta Herzog; Eva Gottwein; Nikolaus Rajewsky
Journal:  Mol Cell       Date:  2014-05-22       Impact factor: 17.970

7.  A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rγnull mice.

Authors:  Isaac W Boss; Peter E Nadeau; Jeffrey R Abbott; Yajie Yang; Ayalew Mergia; Rolf Renne
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 8.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

9.  Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs.

Authors:  Hal P Bogerd; Rebecca L Skalsky; Edward M Kennedy; Yuki Furuse; Adam W Whisnant; Omar Flores; Kimberly L W Schultz; Nicole Putnam; Nicholas J Barrows; Barbara Sherry; Frank Scholle; Mariano A Garcia-Blanco; Diane E Griffin; Bryan R Cullen
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles.

Authors:  Shipra Malik; Jihoon Lim; Frank J Slack; Demetrios T Braddock; Raman Bahal
Journal:  J Control Release       Date:  2020-08-21       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.